Safety and Efficacy of Anlotinib in the Treatment of Recurrent Craniopharyngioma

NCT06970145 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

57

Enrollment

OTHER

Sponsor class

Conditions

Craniopharyngiomas

Interventions

DRUG: Anlotinib

Sponsor

Nanfang Hospital, Southern Medical University